We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
In 1993, the first acetylcholinesterase inhibitor (AChEI), tacrine, was approved by the FDA for treatment of dementia. This class of medication is thought to work by raising levels of acetylcholine, an important neurotransmitter in the brain. There was a lot of excitement about the approval of tacrine, but almost immediately severe side effects including serious liver damage were encountered, and the use of the drug dwindled and disappeared almost overnight. I don’t think I ever wrote a prescription for tacrine. Three years later the first relatively safe AChEI, donepezil (trade name Aricept), was approved and it is still going strong. Within a few years, two similar drugs, rivastigmine and galantamine, were approved. They were all about equally effective. They all had similar side effects, but sometimes a person could tolerate one better than another. For an individual patient, it was hard to tell for sure if they were effective or not. A few of my patients had remarkable improvement and others didn’t seem to change much at all. For others, the side effects were intolerable. Most common were nausea, cramps, and diarrhea as well as nightmares and insomnia. I found that starting my patients at a very low dose, lower than recommended, and very slowly increasing the dose over several months would usually avoid the side effects.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.